EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

COST CONTROL OF PROTON PUMP INHIBITOR UTILIZATION AMONG NATIONAL HEALTH INSURANCE INPATIENTS AT TERTIARY HOSPITAL IN SURABAYA

Faradisa Umahati, Yulistiani Yulistiani, Nur Fauzi Hamidi, Linda Sutrisno, Desak Made Rendang Dianrana Dewi

JURNAL FARMASI KRYONAUT · 31.07.2026 · 5 (2) · 146-157

DOI: 10.59969/jfk.v5i2.204 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JURNAL FARMASI KRYONAUT, online erschienen am 31.07.2026. Verfasst von Faradisa Umahati und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proton pump inhibitors (PPIs) are widely used for the management of acid-related gastrointestinal disorders. Although their clinical efficacy is generally comparable, differences in acid-suppressive potency, duration of action, and acquisition costs may influence prescribing patterns and healthcare expenditures. This study aims to evaluate PPI utilization patterns and costs among hospitalized patients at a tertiary hospital in Surabaya, Indonesia, during 2023–2024 and to identify potential cost-control measures. This retrospective descriptive study analyzed PPI utilization data from the hospital information system for 2023–2024 and pharmacy billing records of National Health Insurance (JKN) patients from October to December 2024. Four oral and five injectable PPI formulations were utilized during the study period. Generic omeprazole, in both oral and injectable forms, accounted for the largest proportion of PPI use. Although injectable lansoprazole was prescribed less frequently, it contributed substantially to overall PPI expenditures. Omeprazole, lansoprazole, and pantoprazole were the most commonly prescribed PPIs among JKN patients. Pantoprazole, despite not being included in the hospital formulary, continued to be used and showed an increasing utilization trend. A shift in prescribing patterns from omeprazole to lansoprazole and pantoprazole in December 2024 was associated with increased costs. Omeprazole represented the highest utilization volume, whereas lansoprazole accounted for the largest share of PPI-related expenditures. Cost-control strategies should focus on optimizing formulary compliance and ensuring the appropriate use of higher-cost PPIs. Further studies evaluating clinical outcomes and the impact of formulary restrictions on lansoprazole use are warranted.

Zitieren

APA

Umahati, F., Yulistiani, Y., Hamidi, N. F., Sutrisno, L., & Dewi, D. M. R. D. (2026). COST CONTROL OF PROTON PUMP INHIBITOR UTILIZATION AMONG NATIONAL HEALTH INSURANCE INPATIENTS AT TERTIARY HOSPITAL IN SURABAYA. JURNAL FARMASI KRYONAUT, 5(2), 146-157. https://doi.org/10.59969/jfk.v5i2.204

Vancouver

Umahati F, Yulistiani Y, Hamidi NF, Sutrisno L, Dewi DMRD. COST CONTROL OF PROTON PUMP INHIBITOR UTILIZATION AMONG NATIONAL HEALTH INSURANCE INPATIENTS AT TERTIARY HOSPITAL IN SURABAYA. JURNAL FARMASI KRYONAUT. 2026;5(2):146-157. doi:10.59969/jfk.v5i2.204

BibTeX
@article{Umahati2026,
  author = {Umahati, Faradisa and Yulistiani, Yulistiani and Hamidi, Nur Fauzi and Sutrisno, Linda and Dewi, Desak Made Rendang Dianrana},
  title = {COST CONTROL OF PROTON PUMP INHIBITOR UTILIZATION AMONG NATIONAL HEALTH INSURANCE INPATIENTS AT TERTIARY HOSPITAL IN SURABAYA},
  journal = {JURNAL FARMASI KRYONAUT},
  year = {2026},
  volume = {5},
  number = {2},
  pages = {146--157},
  doi = {10.59969/jfk.v5i2.204}
}
Kostenlos starten →